Arthrosamid vs Hyaluronic Acid vs Placebo Injection in Moderate to Severe Knee Osteoarthritis: a Randomized Controlled Trial

This current research focuses on the effectiveness of polyacrylamide hydrogel (PAH) or Arthrosamid injections for the treatment of knee osteoarthritis (OA) in comparison with hyaluronic acid viscosupplementation (HA), which is a common injectable for treating knee OA. PAH is a permanent injectable hydrogel (2.5% cross-linked polyacrylamide, 97.5% water) recently approved in Canada for treating knee osteoarthritis. PAH is non-biodegradable, integrates into the synovial membrane, may act as an IL-1 receptor agonist, and has shown non-inferiority—and in some subgroups, superiority—to hyaluronic acid (HA), with potential efficacy lasting at least 5 years. It has a strong safety record from two decades of use in Europe for treating OA and other conditions. This study will be the first triple-blinded randomized trial comparing PAH to HA and placebo to guide clinical decision-making.